- Home
- SLS vs DOUG Comparison
SLS vs DOUG Comparison
Compare SLS & DOUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLS
- DOUG
- Stock Information
- Founded
- SLS 2012
- DOUG 1911
- Country
- SLS United States
- DOUG United States
- Employees
- SLS N/A
- DOUG N/A
- Industry
- SLS Biotechnology: Pharmaceutical Preparations
- DOUG Building operators
- Sector
- SLS Health Care
- DOUG Real Estate
- Exchange
- SLS Nasdaq
- DOUG Nasdaq
- Market Cap
- SLS 169.6M
- DOUG 161.5M
- IPO Year
- SLS N/A
- DOUG N/A
- Fundamental
- Price
- SLS $1.85
- DOUG $2.49
- Analyst Decision
- SLS
- DOUG
- Analyst Count
- SLS 0
- DOUG 0
- Target Price
- SLS N/A
- DOUG N/A
- AVG Volume (30 Days)
- SLS 3.6M
- DOUG 1.0M
- Earning Date
- SLS 08-12-2025
- DOUG 08-06-2025
- Dividend Yield
- SLS N/A
- DOUG N/A
- EPS Growth
- SLS N/A
- DOUG N/A
- EPS
- SLS N/A
- DOUG N/A
- Revenue
- SLS N/A
- DOUG $1,048,791,000.00
- Revenue This Year
- SLS N/A
- DOUG $17.61
- Revenue Next Year
- SLS N/A
- DOUG N/A
- P/E Ratio
- SLS N/A
- DOUG N/A
- Revenue Growth
- SLS N/A
- DOUG 11.36
- 52 Week Low
- SLS $0.77
- DOUG $1.17
- 52 Week High
- SLS $2.27
- DOUG $3.20
- Technical
- Relative Strength Index (RSI)
- SLS 52.48
- DOUG 51.83
- Support Level
- SLS $1.88
- DOUG $2.27
- Resistance Level
- SLS $2.27
- DOUG $2.61
- Average True Range (ATR)
- SLS 0.17
- DOUG 0.12
- MACD
- SLS -0.00
- DOUG -0.01
- Stochastic Oscillator
- SLS 52.60
- DOUG 56.58
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.